James J. Beaudoin

649 total citations
22 papers, 492 citations indexed

About

James J. Beaudoin is a scholar working on Oncology, Epidemiology and Pharmacology. According to data from OpenAlex, James J. Beaudoin has authored 22 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Epidemiology and 5 papers in Pharmacology. Recurrent topics in James J. Beaudoin's work include Drug Transport and Resistance Mechanisms (9 papers), Liver Disease Diagnosis and Treatment (7 papers) and Genetic and Kidney Cyst Diseases (5 papers). James J. Beaudoin is often cited by papers focused on Drug Transport and Resistance Mechanisms (9 papers), Liver Disease Diagnosis and Treatment (7 papers) and Genetic and Kidney Cyst Diseases (5 papers). James J. Beaudoin collaborates with scholars based in United States, Finland and United Kingdom. James J. Beaudoin's co-authors include Kim L. R. Brouwer, Melina M. Malinen, Andrew Z. Wang, Alexander V. Kabanov, Rainer Jordan, Jacqueline Bezençon, Natasha Vinod, Herdis Bludau, Xiaomeng Wan and Naoki Makita and has published in prestigious journals such as Biomaterials, International Journal of Molecular Sciences and Pharmacology & Therapeutics.

In The Last Decade

James J. Beaudoin

21 papers receiving 485 citations

Peers

Countries citing papers authored by James J. Beaudoin

Since Specialization

Citations

This map shows the geographic impact of James J. Beaudoin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James J. Beaudoin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James J. Beaudoin more than expected).

Fields of papers citing papers by James J. Beaudoin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James J. Beaudoin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James J. Beaudoin. The network helps show where James J. Beaudoin may publish in the future.

Co-authorship network of co-authors of James J. Beaudoin

This figure shows the co-authorship network connecting the top 25 collaborators of James J. Beaudoin. A scholar is included among the top collaborators of James J. Beaudoin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James J. Beaudoin. James J. Beaudoin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modeling and Simulation of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended‐Release and Immediate‐Release Formulations in Healthy Adults Using the Quantitative Systems Toxicology Software Platform DILIsym 2025 ·CPT Pharmacometrics & Systems Pharmacology ·James J. Beaudoin, (unknown), Brett A. Howell, (unknown), (unknown), Jeffrey L. Woodhead, (unknown), (unknown), (unknown), Evren Atillasoy	1
2	Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease 2024 ·British Journal of Clinical Pharmacology ·(unknown), James J. Beaudoin, Vimal K. Derebail, William A. Murphy, (unknown), (unknown), (unknown), (unknown), Wei Jia, Paul W. Stewart, Kim L. R. Brouwer	1
3	Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition 2023 ·Frontiers in Pharmacology ·James J. Beaudoin, Kyunghee Yang, Jeffry Adiwidjaja, (unknown), Paul B. Watkins, Scott Q. Siler, Brett A. Howell, Jeffrey L. Woodhead	6
4	The Combination of a Human Biomimetic Liver Microphysiology System with BIOLOGXsym, a Quantitative Systems Toxicology (QST) Modeling Platform for Macromolecules, Provides Mechanistic Understanding of Tocilizumab- and GGF2-Induced Liver Injury 2023 ·International Journal of Molecular Sciences ·James J. Beaudoin, (unknown), Mark T. Miedel, Albert Gough, (unknown), (unknown), Kari E. Wong, Rangaprasad Sarangarajan, (unknown), Lisl K.M. Shoda, Scott Q. Siler, D. Lansing Taylor, Brett A. Howell, Lawrence A. Vernetti, Kyunghee Yang	6
5	Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH) 2022 ·Clinical Pharmacology & Therapeutics ·William A. Murphy, Jeffry Adiwidjaja, Noora Sjöstedt, Kyunghee Yang, James J. Beaudoin, (unknown), Scott Q. Siler, Sibylle Neuhoff, Kim L. R. Brouwer	26
6	Identification of Key Amino Acids that Impact Organic Solute Transporter α/β (OSTα/β) 2021 ·Molecular Pharmacology ·William A. Murphy, James J. Beaudoin, Tuomo Laitinen, Noora Sjöstedt, Melina M. Malinen, Henry Ho, Peter W. Swaan, Paavo Honkakoski, Kim L. R. Brouwer	0
7	Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis 2021 ·Alcoholism Clinical and Experimental Research ·James J. Beaudoin, Tiebing Liang, Qing Tang, Bubu A. Banini, Vijay H. Shah, Arun J. Sanyal, Naga Chalasani, Samer Gawrieh	8
8	Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside 2020 ·Pharmacology & Therapeutics ·James J. Beaudoin, Kim L. R. Brouwer, Melina M. Malinen	47
9	Endogenous Coproporphyrin I and III are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TR−) Rats 2020 ·Journal of Pharmaceutical Sciences ·Jacqueline Bezençon, Chitra Saran, (unknown), James J. Beaudoin, Yueping Zhang, Hong Shen, John K. Fallon, Philip C. Smith, Henriette E. Meyer zu Schwabedissen, Kim L. R. Brouwer	14
10	Role of Organic Solute Transporter Alpha/Beta in Hepatotoxic Bile Acid Transport and Drug Interactions 2020 ·Toxicological Sciences ·James J. Beaudoin, Jacqueline Bezençon, Noora Sjöstedt, John K. Fallon, Kim L. R. Brouwer	14
11	Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease 2019 ·Drug Metabolism and Disposition ·Jacqueline Bezençon, James J. Beaudoin, Katsuaki Ito, Dong Fu, Sharin E. Roth, William J. Brock, Kim L. R. Brouwer	16
12	Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments 2018 ·Biomaterials ·Xiaomeng Wan, James J. Beaudoin, Natasha Vinod, Yuanzeng Min, Naoki Makita, Herdis Bludau, Rainer Jordan, Andrew Z. Wang, Marina Sokolsky‐Papkov, Alexander V. Kabanov	159
13	Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease 2018 ·International Journal of Toxicology ·William J. Brock, James J. Beaudoin, (unknown), Mingming Su, Wei Jia, Sharin E. Roth, Kim L. R. Brouwer	16
14	Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease 2018 ·Drug Metabolism and Disposition ·James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock, Kim L. R. Brouwer	12
15	Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury 2018 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Melina M. Malinen, (unknown), Jacqueline Bezençon, James J. Beaudoin, Kim L. R. Brouwer	37
16	Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OSTα/β) 2018 ·Molecular Pharmaceutics ·Melina M. Malinen, (unknown), James J. Beaudoin, Noora Sjöstedt, Paavo Honkakoski, Kim L. R. Brouwer	12
17	Interaction between the patatin‐like phospholipase domain‐containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis 2017 ·Hepatology Communications ·Suthat Liangpunsakul, James J. Beaudoin, Vijay H. Shah, Puneet Puri, Arun J. Sanyal, Patrick S. Kamath, Spencer Lourens, Qing Tang, Barry P. Katz, David W. Crabb, Naga Chalasani	20
18	An exploratory genome-wide analysis of genetic risk for alcoholic hepatitis 2017 ·Scandinavian Journal of Gastroenterology ·James J. Beaudoin, Nanye Long, Suthat Liangpunsakul, Puneet Puri, Patrick S. Kamath, Vijay H. Shah, Arun J. Sanyal, David W. Crabb, Naga Chalasani, Thomas Urban, (unknown)	14
19	The National NeuroAIDS Tissue Consortium (NNTC) Database: an integrated database for HIV-related studies 2015 ·Database ·Mátyás Cserháti, Sanjit Pandey, James J. Beaudoin, Lorena Baccaglini, Chittibabu Guda, Howard S. Fox	5
20	PKCζ and PKMζ are overexpressed in TCF3-rearranged paediatric acute lymphoblastic leukaemia and are associated with increased thiopurine sensitivity 2014 ·Leukemia ·(unknown), James J. Beaudoin, Mirjam W.J. Luijendijk, (unknown), Rob Pieters, Monique L. den Boer	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact